Ire1抑制剂减弱了Candida albicans的致病性,并显示出在抗真菌治疗中应用的潜力
Hua Wang1, Mengyan Li1, Qiuyue Wang1
1Department of Clinical Laboratory, Bethune International Peace Hospital, Shijiazhuang, China.
Frontiers in microbiology
|September 19, 2025
概括
研究人员确定了4μ8c作为Candida albicans中的Ire1酶的新型抑制剂. 这种化合物有效地减少了真菌的致病性和殖民性,提供了一个有前途的新抗真菌策略.
科学领域:
- 微生物学 微生物学
- 菌类学 菌类学是指菌类学.
- 药理学 药理学是指药理学的学科.
背景情况:
- * *Candida albicans*是一种机会性病原体,会引起表面和侵入性感染.
- * 由内网膜应激传感器Ire1介导的未折叠蛋白质反应 (UPR) 对*C. albicans*的生存和毒性至关重要.
- * 向Ire1是一个潜在的新型抗真菌治疗方法.
研究的目的:
- * 为了识别向 *Candida albicans* Ire1.1.的RNase活性的小分子抑制剂.
- * 评估已识别的抑制剂对*C. albicans*病原性的有效性,在体外和体内.
主要方法:
- * 用分子对接来选潜在的Ire1抑制剂.
- *体外测试评估了抑制剂对真菌病原性特征的影响.
- *在体内研究中使用了小鼠肠道殖民模式来验证疗效.
主要成果:
- *预计有三种抑制剂 (MKC8866,STF083010,4μ8c) 能够结合Ire1;只有4μ8c显示出一致的抑制活性.
- *4μ8c显著损害了 *C. albicans* 的形态转变,粘附,花和生物膜形成.
- *4μ8c治疗在小鼠模型中减少了真菌殖民和肠道损伤,增加了对现有的抗真菌药物的敏感性.
结论:
- *通过Ire1对UPR途径的药理抑制是一种可行的抗真菌策略.
- * 化合物4μ8c在降低*C. albicans*的适应性和致病性方面显示出显著的潜力.
- *这项研究为开发针对Ire1.1的新型抗真菌疗法提供了新的见解.
相关概念视频
Fungal Phylum Microsporidia
437
Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
437
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
499
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
499
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K


